If you are searching for Pluvicto in China, you are most likely asking one of three questions: is it actually available here, what does it cost, and which hospital will take me. This page answers all three for a patient coming from outside China.
The short version: Pluvicto is licensed in China, it is not cheap even by local standards, and the real bottleneck is finding a centre with the right nuclear medicine licence rather than the drug itself.
What Pluvicto is
Pluvicto (lutetium-177 vipivotide tetraxetan, marketed in China as 派威妥) is a radioligand therapy. It is not chemotherapy and it is not conventional radiotherapy.
It works by pairing two things: a small molecule that binds to PSMA, a protein found on the surface of most prostate cancer cells, and a radioactive isotope, lutetium-177, which delivers beta radiation to whatever cell the molecule attaches to. Because PSMA is far more common on prostate cancer cells than on healthy tissue, the radiation is concentrated where it is needed.
Is Pluvicto approved in China?
Yes, and it arrived faster than most China watchers expected.
| Date | What happened |
|---|---|
| Nov 2025 | NMPA licensed Pluvicto for advanced metastatic prostate cancer that has progressed after standard systemic therapy — the castration-resistant (mCRPC) setting |
| 26 Aug 2026 | NMPA approved a widened indication: in combination with an androgen receptor pathway inhibitor (ARPI) for adults with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC) |
| — | It is the only PSMA-targeted radioligand therapy licensed in China |
The 2026 expansion was based on the phase 3 PSMAddition trial, which reported a 33% lower risk of progression or death (HR 0.67) and a 20% lower risk of death (HR 0.80) for patients receiving Pluvicto on top of standard of care.
The practical meaning of the two dates: China now covers both the late-line patient who has run out of options and the earlier-line hormone-sensitive patient — the group that, in the US and Europe, has been the fastest-growing part of Pluvicto demand.
What Pluvicto costs in China
Reported Chinese pricing sits around ¥163,000 per dose, given once every 6 weeks for up to 6 doses. A full course is generally quoted at ¥500,000–900,000, and close to ¥1,000,000 once the mandatory 68Ga-PSMA PET/CT staging scan (a few thousand yuan per scan) and supportive care are counted in.
For context, this is reported at roughly 60–70% of the price charged in Western countries — but it is still a six-figure treatment, and two more facts matter:
- It is not on China's national reimbursement list. This is self-pay.
- The PET scan is not optional. No confirmed PSMA-positive scan, no treatment. Budget for it as part of the total, not as an extra.
Prices here are what has been publicly reported and will vary by centre, dose count, and whether the patient needs inpatient support between cycles. Treat them as a planning range, not a quote.
Who qualifies
Eligibility falls into two groups, matching the two approvals:
- Castration-resistant (mCRPC) — cancer has spread beyond the prostate and progressed despite hormonal treatment and at least one line of chemotherapy.
- Metastatic hormone-sensitive (mHSPC) — adults with PSMA-positive disease, treated in combination with an androgen receptor pathway inhibitor.
In both cases the gate is the same: a PSMA PET scan must confirm the tumour is PSMA-positive. A meaningful share of prostate cancers do not express enough PSMA for this therapy to work, and no amount of clinical urgency changes that.
How treatment is given
- Route: intravenous infusion in a nuclear medicine department — not a standard oncology ward.
- Schedule: once every 6 weeks, up to 6 doses.
- Stay: most centres require only a single day of hospitalisation per cycle.
- After each dose: radiation-safety instructions. This is a radioactive drug, and there are precautions for close contact in the days following an infusion.
Because the schedule is spread over roughly eight months, the patient's time in China is not one long trip. Most international patients do the staging and first infusion, then return home between cycles — which changes both the cost of the trip and the planning.
The real bottleneck: finding a licensed centre
Here is the part that most pages about Pluvicto skip.
In China, the limiting factor is not the drug. It is the facility: Pluvicto can only be given at a hospital with a licensed nuclear medicine department, radioisotope handling approval, and PSMA PET/CT capability. Those are not universal even among top-tier hospitals.
Shanghai Pudong Hospital performed the city's first injection. Availability is expanding, but it is still uneven between cities — and it has to be confirmed hospital by hospital, for each case, before a patient books a flight.
This is precisely the kind of verification we do. Because we hold the hospital relationships rather than relying on a public list, we can ask a specific nuclear medicine department whether they currently accept an international patient for Pluvicto, what their current dose availability is, and what the case needs before a quote is issued — instead of sending you to a page that was accurate six months ago.
We do not list named hospitals as offering Pluvicto unless a centre has confirmed it for the specific case in front of us. A directory that claims availability it cannot verify is worse than no directory.
The path for an international patient
- Records review. Send your PSMA PET/CT, pathology, prior treatment history (hormonal therapy, chemotherapy, ARPI), and current PSA. We review whether you fit either approved indication.
- Confirm a centre. We contact nuclear medicine departments that hold the licence and ask, for your case specifically, whether they are taking international patients and what their current availability is.
- Written quote. Dose count, per-dose price, imaging, and inpatient support — itemised, in English, before you commit to anything.
- Visa and timing. China has no medical visa; most patients enter on an M (business) visa, with S2 as a backup. See our visa guide for the current wording, because this is widely misreported.
- Staging, then first infusion. The PSMA PET/CT is repeated or confirmed at the treating centre, then cycle one is given.
- Between cycles. Most patients return home and come back every 6 weeks, rather than staying in China for eight months.
To start, send your case through our case review form. We will tell you plainly whether Pluvicto is realistic for your situation — including if the answer is no.
Related reading
- Proton therapy in China — the other advanced radiotherapy modality patients ask about
- CAR-T and cell therapy in China — how China's other advanced-therapy pathway works for international patients
- Urology in China and Oncology in China — the departments that handle these cases
- Hospital directory — how we vet the hospitals we work with
FAQ
Is Pluvicto available in China? Yes — licensed in November 2025 for castration-resistant disease, and widened in August 2026 to PSMA-positive metastatic hormone-sensitive prostate cancer in combination with an ARPI. It is the only PSMA-targeted radioligand therapy licensed in China. It is not on the national reimbursement list.
How much does it cost? Reported at roughly ¥163,000 per dose, up to 6 doses every 6 weeks — a full course around ¥500,000–900,000, approaching ¥1,000,000 with the required PSMA PET/CT and supportive care. Roughly 60–70% of Western pricing, self-pay.
Who qualifies? Either castration-resistant disease that has progressed after hormonal therapy and at least one chemotherapy line, or PSMA-positive metastatic hormone-sensitive disease alongside an ARPI. A PSMA PET scan must confirm PSMA positivity first.
How is it given? An intravenous infusion in a nuclear medicine department, every 6 weeks, up to 6 doses, usually with a single day of hospitalisation per cycle.
Can I come from abroad for it? Yes, if a licensed centre accepts your case. The constraint is the facility, not the drug — availability must be confirmed hospital by hospital before you travel, and that is what we do on your behalf.
This article is for general information and is not medical advice. Pluvicto is a prescription radiopharmaceutical; whether it is appropriate for you depends on your PSMA PET findings, prior treatments, blood counts and kidney function, and must be decided by a qualified nuclear medicine physician or oncologist. Prices reflect publicly reported figures as of September 2026 and will vary by centre. We do not provide medical opinions — clinical decisions rest with the treating hospital.
